November 23, 2016 09:28 AM ESTUpdated 09:50 AM
News Briefing

Pfiz­er blue­prints $200M R&D cam­pus; Gala­pa­gos bags $50M mile­stone from Gilead

Shehla Shakoor

Managing Director

Pfiz­er is build­ing a new R&D cam­pus in St. Louis for more than 600 staffers cur­rent­ly de­ployed at two near­by lo­ca­tions. This new con­sol­i­da­tion project …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times